SCHEMBL6462545

SCHEMBL6462545

C=CCCCCC(O)CN1CCN(c2cccc3c2CCc2ccccc2C3)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 9/20 0.39
DRD3 P35462 9/20 0.39
DRD4 P21917 3/20 0.38
HTR1A P08908 1/20 0.38
HTR2A P28223 1/20 0.38
HTR2C P28335 1/20 0.38
MAPT P10636 4/20 0.38
ALDH1A1 P00352 3/20 0.38
LMNA P02545 3/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
GAA P10253 2/20 0.36
TP53 P04637 1/20 0.36
MAPK1 P28482 1/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CARM1 Q86X55 1/20 0.35
OPRM1 P35372 1/20 0.35
SCN1A P35498 1/20 0.35
SCN5A Q14524 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6463464 0.99 DRD2 (0.39) DRD2DRD3DRD4HTR1AHTR2A
SCHEMBL6460817 0.93 DRD2 (0.41) DRD2DRD3DRD4HTR1AHTR2A
SCHEMBL6467034 0.91 DRD2 (0.37) DRD2DRD3DRD4HTR1A
SCHEMBL6463756 0.86 DRD2 (0.42) DRD2DRD3DRD4HTR1AHTR2A
SCHEMBL6466061 0.83 DRD2 (0.38) DRD2DRD3HTR1AHTR2AHTR2C
SCHEMBL9403868 0.76 L3MBTL1 (0.58) MAPTALDH1A1LMNAMEN1KMT2A
SCHEMBL6461339 0.73 ATM (0.32) DRD2DRD3DRD4HTR1AHTR2A
SCHEMBL6465693 0.69 HTR1A (0.45) DRD2DRD3DRD4HTR1AALDH1A1
SCHEMBL6903656 0.68 ATM (0.37) DRD2DRD3DRD4HTR1AHTR2A
SCHEMBL9186589 0.68 MAPT (0.55) DRD2DRD3HTR1AHTR2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6881841-B2 Dibenzosuberanyl piperazine derivatives and drug-resistance overcoming agents containing the derivatives Takeuchi, Tsutomu (JP) 2005-04-19 US claimed
US-20040029895-A1 Dibenzosberanyl piperazine derivatives and drug-resistance overcoming agents containing the derivatives TAKAYANAGI, HIROAKI (JP) 2004-02-12 US claimed
EP-1336608-A1 DIBENZOSBERANYL PIPERAZINE DERIVATIVES AND DRUG-RESISTANCE OVERCOMING AGENTS CONTAINING THE DERIVATIVES POLA CHEMICAL INDUSTRIES, INC. (JP) 2003-08-20 EP claimed
US-6881841-B2 Dibenzosuberanyl piperazine derivatives and drug-resistance overcoming agents containing the derivatives Takeuchi, Tsutomu (JP) 2005-04-19 US disclosed
US-20040029895-A1 Dibenzosberanyl piperazine derivatives and drug-resistance overcoming agents containing the derivatives TAKAYANAGI, HIROAKI (JP) 2004-02-12 US disclosed
EP-1336608-A1 DIBENZOSBERANYL PIPERAZINE DERIVATIVES AND DRUG-RESISTANCE OVERCOMING AGENTS CONTAINING THE DERIVATIVES POLA CHEMICAL INDUSTRIES, INC. (JP) 2003-08-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040029895-A1 Dibenzosberanyl piperazine derivatives and drug-resistance overcoming agents containing the derivatives ABCC1, ABCB1, SLC11A2 DRD2 1484/4885DRD3 1857/4885DRD4 2875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.